Stason Pharmaceuticals, Inc.   Report issue

Contributed to NME For profit Phase 2
Founded: Irvine CA United States (1994)

Organization Overview

First Clinical Trial
2015
NCT02693093
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

STASON PHARMS

Active Ingredients

Marketed Drugs (1)

mercaptopurine (purinethol) (1953 NDA)

Drugs in Phase 2 Trials (1)

camostat mesylate (1 trial)

Indications

Approved Indications


 

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pancreatitis (Phase 2)

Pancreatitis, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1